Incyte Corp. (INCY)
124.37
-3.37
(-2.64%)
USD |
NASDAQ |
Aug 28, 16:00
123.05
-1.32
(-1.06%)
After-Hours: 20:00
Incyte Free Cash Flow : 1.890B for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.890B |
| March 31, 2026 | 1.421B |
| December 31, 2025 | 1.330B |
| September 30, 2025 | 1.172B |
| June 30, 2025 | 945.58M |
| March 31, 2025 | 288.81M |
| December 31, 2024 | 235.17M |
| September 30, 2024 | 16.80M |
| June 30, 2024 | -139.52M |
| March 31, 2024 | 790.77M |
| December 31, 2023 | 449.00M |
| September 30, 2023 | 565.93M |
| June 30, 2023 | 697.64M |
| March 31, 2023 | 560.86M |
| December 31, 2022 | 892.11M |
| September 30, 2022 | 710.61M |
| June 30, 2022 | 664.98M |
| March 31, 2022 | 609.20M |
| December 31, 2021 | 568.48M |
| September 30, 2021 | 543.48M |
| June 30, 2021 | 449.83M |
| March 31, 2021 | 568.72M |
| December 31, 2020 | -311.98M |
| September 30, 2020 | -265.56M |
| June 30, 2020 | -107.63M |
| Date | Value |
|---|---|
| March 31, 2020 | -227.49M |
| December 31, 2019 | 632.59M |
| September 30, 2019 | 588.85M |
| June 30, 2019 | 475.95M |
| March 31, 2019 | 391.89M |
| December 31, 2018 | 262.74M |
| September 30, 2018 | 98.60M |
| June 30, 2018 | -56.90M |
| March 31, 2018 | 6.941M |
| December 31, 2017 | -204.01M |
| September 30, 2017 | -19.92M |
| June 30, 2017 | 39.90M |
| March 31, 2017 | -110.20M |
| December 31, 2016 | 184.48M |
| September 30, 2016 | 169.09M |
| June 30, 2016 | 84.81M |
| March 31, 2016 | 160.64M |
| December 31, 2015 | 60.53M |
| September 30, 2015 | 36.66M |
| June 30, 2015 | 59.05M |
| March 31, 2015 | 24.60M |
| December 31, 2014 | -1.885M |
| September 30, 2014 | -43.58M |
| June 30, 2014 | -74.57M |
| March 31, 2014 | -53.55M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Mirum Pharmaceuticals, Inc. | -263.74M |
| Regeneron Pharmaceuticals, Inc. | 3.575B |
| Eli Lilly & Co. | 13.56B |
| AbbVie, Inc. | 18.21B |
| Biogen, Inc. | 2.49B |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 507.66M |
| Cash from Investing (Quarterly) | -51.79M |
| Cash from Financing (Quarterly) | 65.46M |
| Free Cash Flow Per Share (Quarterly) | 2.378 |
| Free Cash Flow to Equity (Quarterly) | 496.41M |
| Free Cash Flow to Firm (Quarterly) | 495.70M |
| Free Cash Flow Yield | 7.40% |